[Skip to Navigation]
From the JAMA Network
August 2017

Do the Data on Scalp Cooling for Patients With Breast Cancer Warrant Broad Adoption?

Author Affiliations
  • 1Medical Oncology, Swedish Cancer Institute, Seattle, Washington
  • 2Web Editor, JAMA Oncology, Seattle, Washington
JAMA Oncol. 2017;3(8):1130-1131. doi:10.1001/jamaoncol.2017.0051

Although chemotherapy-induced alopecia does not rank among the more worrisome adverse effects of cancer treatment, it is one that patients, especially women, rank as among the more dreaded.1 It is also among the most visible reminders to patients and those around them of being a recipient of cancer treatment, believed to be a product of the rapid cell turnover of hair follicles, making them vulnerable to the DNA-damaging effect of many conventional chemotherapy agents.2 In this setting, an intervention that can prevent or reduce the severity of chemotherapy-induced alopecia would be eagerly welcomed by most patients and oncologists.